Capstan Medical Raises $110M for Innovative Robotics in Heart Disease Treatment

Significant Funding for Heart Health Innovation

Capstan Medical, a pioneering company specializing in robotic-assisted treatment for heart valve disease, has successfully raised a staggering $110 million in its latest funding round. This oversubscribed Series C funding was led by Eclipse, a venture capital firm known for investing in health tech innovations, and also saw participation from other prominent investors such as Yu Galaxy, Intuitive Ventures, and Gideon Strategic Partners.

Heart disease remains a critical health issue globally, accounting for the highest mortality rates. In the United States alone, a person dies from heart disease every 33 seconds, and more than 7 million people are currently living with heart valve disease. This condition primarily involves complications with the mitral and tricuspid valves, which are essential to maintaining proper blood flow in the heart. Conventional treatment approaches often involve high-risk open-heart surgeries that are not suitable for all patients, while existing catheter-based methods often exclude many individuals due to their complexity and risks.

Capstan Medical is addressing these challenges by developing advancements in minimally invasive procedures. Their innovative approach merges sophisticated heart valve implants with advanced robotic-assisted catheter technology, enabling treatments that are potentially safer and more effective for a wider range of patients.

Maggie Nixon, CEO of Capstan Medical, expressed her enthusiasm about the funding, stating that the company’s mission is to leverage its robotic platform to significantly broaden treatment options for those suffering from heart valve disease. She highlighted, "Percutaneous interventions will enable us to increase the treatment avenues available for millions. With our comprehensive portfolio of robotic tools and implants, we feel poised to meet the urgent needs of this underserved population."

Since its inception in 2020, Capstan Medical has rapidly expanded into a force within the health tech arena, assembling a talent-rich workforce that now exceeds 75 employees focused on engineering, operations, clinical expertise, and regulatory compliance. The new funding will allow the company to broaden its clinical and development efforts, paving the way for pivotal clinical trials in the future.

Justin Butler from Eclipse emphasized the transformative role that robotics could play in improving access to life-saving cardiovascular solutions. He stated, "As we step into a new era of medical treatment, Capstan Medical stands at the forefront of integrating robotics into heart disease solutions, promising significant advancements in the field."

Capstan’s commitment to changing the landscape of heart disease treatment positions it as a company to watch in the upcoming years. With its innovative robotic platform, the company aims to create a new standard for minimally invasive heart valve interventions.

For further insights and updates, you can visit Capstan Medical's official website at www.capstanmedical.com.

About Capstan Medical

Established in 2020, Capstan Medical is devoted to developing state-of-the-art minimally invasive interventions for heart valve issues, presenting the first catheter-based robotic delivery platform and next-generation heart valve implants. Their overarching goal is to redefine how heart valve diseases are addressed, ensuring that more patients have access to safer treatment options.